Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963366 | 0.65 | ACHE (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL31475657 | 0.65 | ACHE (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL20420239 | 0.62 | LIMK1 (0.35) | — | |
| SCHEMBL23992750 | 0.61 | KDM4E (0.32) | ALDH1A1KDM4E | |
| SCHEMBL17413773 | 0.61 | — | — | |
| SCHEMBL23676577 | 0.60 | KDM4E (0.33) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30303130 | 0.59 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1CDK8CDK19ALDH1A1 | |
| SCHEMBL21865977 | 0.59 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1CDK8CDK19ALDH1A1 | |
| SCHEMBL17008992 | 0.59 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1CDK8CDK19ALDH1A1 | |
| SCHEMBL23580267 | 0.58 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1CDK8CDK19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153803-B2 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090259044-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259044-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | SIRT2, SIRT1, SIRT3 | HSP90AA1 357/4885HSP90AB1 212/4885CDK8 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.